Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 4,113 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Healthy
Interventions: ICD; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Colorectal Neoplasms, Diarrhea
Interventions: Investigational drug, Irinotecan, 5-fluorouracil, Leucovorin; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 28
States / cities: Little Rock, Arkansas • Anaheim, California • Concord, California + 24 more

Conditions: Stroke
Interventions: Transcranial Magnetic Stimulation (TMS), Carbidopa-Levodopa, Methylphenidate, Amphetamine Sulfate, Placebo, Sham Transcranial Magnetic Stimulation (TMS), Transcranial Magnetic Stimulation (TMS) Training; Other · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Gastrointestinal Graft vs Host Disease
Interventions: orBec, Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Hackensack, New Jersey • Buffalo, New York • Nashville, Tennessee

Conditions: Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
Interventions: WAL0921, Placebo; Drug
Lead sponsor: Walden Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more

Conditions: Healthy, Actinic Keratosis
Interventions: PEP005 Gel; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Neuroectodermal Tumors, Primitive, Liver Neoplasms, Osteosarcoma, Other Childhood Cancers Using Cisplatin-based Regimens
Interventions: N-Acetylcysteine; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 1 Year to 21 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Small Cell Lung Cancer
Interventions: Pembrolizumab, MK-4830, Boserolimab, Lenvatinib, Etoposide, Cisplatin, Carboplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 14
States / cities: Gilbert, Arizona • Aurora, Colorado • Atlanta, Georgia + 10 more

Conditions: Retinal Dystrophies
Interventions: SS-HH-OCT; Device
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 8 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Solid Tumors
Interventions: Tomivosertib (eFT-508); Drug
Lead sponsor: Effector Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Tucson, Arizona • Long Beach, California • Los Angeles, California + 15 more

Conditions: Anxiety, Pain, Procedural
Interventions: Lavandula angustifolia, Aura Cacia, Placebo; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Social Media, Digital Well-being
Interventions: Friction-Based Smartphone Intervention; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 24 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Renal Transplant
Interventions: Zortress® /Everolimus; Drug
Lead sponsor: University of Kentucky; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Menopause, Aging
Interventions: Elagolix Oral Tablet, Estradiol patch, cellulose placebo, placebo patch; Drug · Other
Lead sponsor: Penn State University; Other
Eligibility: 42 Years to 64 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
Interventions: Zanubrutinib; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Stroke, Obesity &Amp; Overweight
Interventions: Strong SC, StrongPeople StrongHearts; Behavioral
Lead sponsor: Clemson University; Other
Eligibility: 45 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Florence, South Carolina

Conditions: Major Depressive Diorder
Interventions: Psilocybin (drug), cognitive behavioral therapy, Minimal supportive therapy; Drug · Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain After Urodynamic Testing
Interventions: Phenazopyridine Hydrochloride 99.5 MG; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Parkinson's Disease
Interventions: rasagiline mesylate, rasagiline mesylate 1.0 mg; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 7
States / cities: Fresno, California • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: Inflammation
Interventions: Occipito-Atlantal Decompression (OA DC), Sham Occipito-Atlantal Decompression (Sham OA DC), Splenic Lymphatic Pump Technique (SpLPT), Sham Splenic Lymphatic Pump Technique (Sham SpLPT), Transcutaneous Auricular Vagus Nerve Stimulation (taVNS), Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS); Procedure · Device
Lead sponsor: Burrell College of Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Las Cruces, New Mexico

Conditions: Sickle Cell Disease, Graft Versus Host Disease
Interventions: Diphenhydramine, Acetaminophen, Methylprednisolone, Meperidine, Alemtuzumab, Thymoglobulin, Fludarabine, Melphalan, Thiotepa, Cyclosporine, Tacrolimus, Methotrexate, Abatacept, Marrow infusion, Sirolimus, Mycophenolate Mofetil; Drug · Procedure
Lead sponsor: Monica Bhatia; Other
Eligibility: 3 Years to 20 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: Stage IV Lung Adenocarcinoma
Interventions: Certolizumab, cisplatin, pemetrexed; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more

Conditions: Chronic Pain, Chronic Low Back Pain
Interventions: transcranial Direct Current Stimulation (tDCS), Transcranial Ultrasound (TUS); Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Cancer
Interventions: Medically Tailored Grocery Plus Nutrition Counseling Group, Experimental: Medically Tailored Grocery Group, Standard of Care Group with Delayed Medically Tailored Grocery Delivery; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Comparison of Fixed Tilt and Tuned Waveforms in Right-sided Implants

A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

Neurobiological Principles Applied to the Rehabilitation of Stroke Patients

Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)

Study of WAL0921 in Patients With Glomerular Kidney Diseases

PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects

NAC to Prevent Cisplatin-induced Hearing Loss

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Lavender Aromatherapy to Decrease Anxiety/Pain Perception During Office Hysteroscopy

Digital Habit Interventions

Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients

Role of Menopause in Thermoregulation

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

Fueling Strong Hearts for a Strong South Carolina

RCT of Psilocybin-assisted CBT for Depression

Effectiveness of Phenazopyridine for Pain Following Urodynamics

Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.

Anti-inflammatory Actions of Osteopathic Manipulative Treatment

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas

Effects of tDCS and TUS on the Perception of Pain and Functional Limitations Due to Non-Specific Chronic Low Back Pain

Nourishing Hope: The Impact of Nutrition in Cancer Treatment and Recovery in Maine